Literature DB >> 20676153

Canadian Ophthalmological Society policy statement on the medical use of marijuana for glaucoma.

Yvonne M Buys, Paul E Rafuse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20676153     DOI： 10.3129/i10-069

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN： 0008-4182            Impact factor:   1.882


× No keyword cloud information.
  5 in total

Review 1.  A review of systemic medications that may modulate the risk of glaucoma.

Authors:  Annie Wu; Anthony P Khawaja; Louis R Pasquale; Joshua D Stein
Journal:  Eye (Lond)       Date:  2019-10-08       Impact factor: 3.775

Review 2.  Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders.

Authors:  Katherine A Belendiuk; Lisa L Baldini; Marcel O Bonn-Miller
Journal:  Addict Sci Clin Pract       Date:  2015-04-21

3.  Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.

Authors:  Goutham R Adelli; Prakash Bhagav; Pranjal Taskar; Tushar Hingorani; Sara Pettaway; Waseem Gul; Mahmoud A ElSohly; Michael A Repka; Soumyajit Majumdar
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-04-01       Impact factor: 4.799

Review 4.  Marijuana for Glaucoma: A Recipe for Disaster or Treatment?

Authors:  Xiaoshen Sun; Chaoying S Xu; Nisha Chadha; Allshine Chen; Ji Liu
Journal:  Yale J Biol Med       Date:  2015-09-03

Review 5.  Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and Pain.

Authors:  James T Toguri; Meggie Caldwell; Melanie E M Kelly
Journal:  Front Pharmacol       Date:  2016-09-15       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.